MDASI Chronic Graft-vs-Host Disease Module
The MD Anderson Symptom Inventory for chronic graft-versus-host disease (MDASI-cGVHD) is a treatment-specific MDASI module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-cGVHD also assesses 5 symptoms specific to chronic graft-versus-host disease:
- muscle weakness
- skin problems
- eye problems
- joint stiffness or soreness
- changes in sexual function
Order the MDASI-cGVHD
MDASI-cGVHD Features
- Purpose: To assess the severity of multiple symptoms related to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by chronic graft-versus-host disease and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.75 to 0.91
MDASI-cGVHD Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English |
MDASI User's Guide
In response to the FDA's 2009 guidance for the pharmaceutical industry on the use of PRO measures in medical product development to support labeling claims, we have prepared a MDASI User's Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-cGVHD. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-cGVHD References
Validation
Williams LA, Couriel DR, Mendoza TR, et al. A new measure of symptom burden in chronic graft-versus-host disease [abstract]. American Society for Blood and Marrow Transplantation 2010 BMT Tandem Meetings, Orlando FL, Feb 24-28, 2010. Biol Blood Marrow Transplant 16(2 Suppl 2): S177, 2010; Abstract #60.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 89: 1634-1646, 2000.
Clinical Application
Lee SJ, Williams LA. Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials. Biol Blood Marrow Transplant 16(3): 295-300, 2010.
Wang XS, Giralt SA, Williams LA, et al. Measuring acute GVHD-related symptom burden and inflammatory cytokines during the first 100 days after allogeneic hematopoietic stem cell transplantation [abstract]. Psychoneuroimmunology Research Society 17th Annual Meeting, Dublin, Ireland, Jun 2-5, 2010. Brain Behav Immun 24(Suppl 1): S5, 2010; Abstract #206.
Williams LA, Anderson KO, Wang XS, et al. Patterns of symptom burden in autologous and allogeneic hematopoietic stem cell transplantation [abstract]. American Society of Hematology 51st Annual Meeting and Exposition, New Orleans LA, Dec 5-8, 2009. Blood 114(22), 2009; Abstract #1396.
Williams LA, Neumann JL, Couriel DR, et al. Measuring the symptom burden of chronic graft-versus-host disease [abstract]. American Society for Blood and Marrow Transplantation 2008 BMT Tandem Meeting, San Diego CA, Feb 13-17, 2008. Biol Blood Marrow Transplant 14(2 Suppl 1): 56, 2008; Abstract #147.
Every MDASI Module Contains...
All 13 MDASI core symptoms
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
All 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
The symptom burden of cGVHD cannot be effectively assessed for research and clinical management without a psychometrically sound, easily administered measure. The MDASI-cGVHD is a valid, reliable, and sensitive measure of cGVHD symptom burden for quantitatively assessing response in cGVHD treatment trials and monitoring the course of cGVHD in clinical care.
Daniel R. Couriel, M.D., M.S.
Professor, University of Utah Health